A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease

• Daniel Todd,

  Affiliation BioFocus, Saffron Walden, United Kingdom

  ⨯
• Ian Gowers,

  Affiliation BioFocus, Saffron Walden, United Kingdom

  ⨯
• Simon J. Dowler,

  Affiliation BioFocus, Saffron Walden, United Kingdom

  ⨯
• Michael D. Wall,

  Affiliation BioFocus, Saffron Walden, United Kingdom

  ⨯
• George McAllister,

  Affiliation BioFocus, Saffron Walden, United Kingdom

  ⨯
• David F. Fischer,

  Affiliation BioFocus, Leiden, Netherlands

  ⨯
• Sipke Dijkstra,

  Affiliation Galapagos, Leiden, Netherlands

  ⨯
• Silvina A. Fratantoni,

  Affiliation Galapagos, Leiden, Netherlands

  ⨯
• Rhea van de Bospoort,

  Affiliation Galapagos, Leiden, Netherlands

  ⨯
• Jessica Veenman-Koepke,

  Affiliation Galapagos, Leiden, Netherlands

  ⨯
• Geraldine Flynn,

  Affiliation Galapagos, Leiden, Netherlands

  ⨯
• Jamshid Arjomand,

  Affiliations CHDI Management/CHDI Foundation, Princeton, New Jersey, United States of America, CHDI Management/CHDI Foundation, Los Angeles, California, United States of America

  ⨯
• Celia Dominguez,

  Affiliations CHDI Management/CHDI Foundation, Princeton, New Jersey, United States of America, CHDI Management/CHDI Foundation, Los Angeles, California, United States of America

  ⨯
• Ignacio Munoz-Sanjuan,

  Affiliations CHDI Management/CHDI Foundation, Princeton, New Jersey, United States of America, CHDI Management/CHDI Foundation, Los Angeles, California, United States of America

  ⨯
• John Wityak,

  Affiliations CHDI Management/CHDI Foundation, Princeton, New Jersey, United States of America, CHDI Management/CHDI Foundation, Los Angeles, California, United States of America

  ⨯
•  [ ... ],
• Jonathan A. Bard

  * E-mail: Jonathan.Bard@CHDIFoundation.org

  Affiliations CHDI Management/CHDI Foundation, Princeton, New Jersey, United States of America, CHDI Management/CHDI Foundation, Los Angeles, California, United States of America

  ⨯
• [ view all ]
• [ view less ]